Tissue research
OS-01
Cosmetic skin-care ingredient; not an approved medicine
In simple words: A skin-care peptide designed to calm “zombie” (senescent) skin cells that drive skin aging.
How it works
It is a senotherapeutic peptide: in lab skin models it reduced markers of cell senescence and supported skin-barrier repair. It is used in topical products, not injected.
Targets: Cellular senescence (skin) · Class: Topical senotherapeutic skin peptide
Uses, latest studies & pairings
Typically used for
- Topical skin care for skin aging (OneSkin products).
- Not injected; not a medicine.
Commonly paired with
- Daily sunscreen and moisturizer, the basics that do the most for skin aging.
Latest studies & news
- 2025
Small studies: an eye-area formula reduced signs of aging, and a 12-week pilot improved the skin barrier.
- 2024
Double-blind, vehicle-controlled trial: improved measures of skin aging.
What the research shows
Human clinical evidence
Human- Double-blind, vehicle-controlled trial: a topical OS-01 formulation improved measures of skin aging (2024).
- Clinical study of an eye-area formulation reported reduced signs of periorbital aging (2025).
- Pilot 12-week study: improved skin-barrier function and reported lower blood inflammation markers (2025). Small studies; more research needed.
Laboratory / in-vitro
In-vitro- Lab and human skin-sample studies showed fewer senescent-cell markers.
Animal and lab results suggest what might happen; they don't prove an effect in people.
Safety & what to watch
- Topical cosmetic use was well tolerated in these studies.
- A cosmetic ingredient, not an approved medicine.
Amounts
No dose is given for unapproved substances. If you are considering it, discuss it with a licensed clinician who knows your history and bloodwork.
📦 My peptide supply kit
The supplies I use, in one Amazon list. Only use them for medicines your clinician prescribes. Never share or reuse needles, and put used ones in a sharps container.
Studies & references
- Double-blind, vehicle-controlled clinical investigation of peptide OS-01 for skin rejuvenation. J Cosmet Dermatol 2024PMID 38400612
- Clinical efficacy of OS-01 peptide formulation in reducing the signs of periorbital skin aging. Int J Cosmet Sci 2025PMID 39788697
- OS-01 peptide topical formulation improves skin barrier function and reduces systemic inflammation markers: a pilot 12-week trial. J Cosmet Dermatol 2025PMID 40193112
Draft profile pending editorial review. Educational only, not medical advice. Never start, stop or change a medicine without your prescriber.